Dermira (DERM) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 4:05 PM EDTQBREXZA (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 First quarter net product sales of $2.5 million Approximately 80% of commercially insured patients have access to QBREXZA End-of-Phase 2 FDA meeting scheduled following positive lebrikizumab study results Balance sheet strengthened through follow-on equity financing
MENLO PARK, Calif.--(BUSINESS WIRE)-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of... More
